Cargando…
The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice
Vascular risk factors, such as type 2 diabetes mellitus (T2DM), are associated with the increased risk of Alzheimer’s disease. One of the common T2DM medications, dipeptidyl peptidase (DPP)-4 inhibitors, have a minimum risk for hypoglycemia and have recently been suggested to ameliorate β-amyloid pa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566831/ https://www.ncbi.nlm.nih.gov/pubmed/31126115 http://dx.doi.org/10.3390/ijms20102539 |
_version_ | 1783426939317387264 |
---|---|
author | Nakaoku, Yuriko Saito, Satoshi Yamamoto, Yumi Maki, Takakuni Takahashi, Ryosuke Ihara, Masafumi |
author_facet | Nakaoku, Yuriko Saito, Satoshi Yamamoto, Yumi Maki, Takakuni Takahashi, Ryosuke Ihara, Masafumi |
author_sort | Nakaoku, Yuriko |
collection | PubMed |
description | Vascular risk factors, such as type 2 diabetes mellitus (T2DM), are associated with the increased risk of Alzheimer’s disease. One of the common T2DM medications, dipeptidyl peptidase (DPP)-4 inhibitors, have a minimum risk for hypoglycemia and have recently been suggested to ameliorate β-amyloid pathology. However, conflicting results have been reported regarding the effects of DPP-4 inhibition on cognitive function and tau pathology. Thus, we investigated whether inhibiting DPP-4 affects tau pathology and cognition in a mouse model of tauopathy with hyperglycemia. Male mice overexpressing the P301S mutant human microtubule-associated protein tau gene (PS19) were fed either a low or high-fat diet. PS19 mice were then administered either linagliptin, a DPP-4 inhibitor, or vehicle, from 6 weeks to 8 months of age. Linagliptin-treated mice exhibited higher levels of glucagon-like peptide-1 and decreased fasting blood glucose, compared with the vehicle-treated mice at 8 months. Linagliptin treatment significantly restored spatial reference memory and increased cerebral blood flow without affecting phosphorylation levels of tau or endothelial nitric oxide synthase (eNOS) in the brain. Linagliptin may ameliorate HFD-induced cognitive worsening in tauopathy, at least partially, by increasing cerebral perfusion via the eNOS-independent pathway. |
format | Online Article Text |
id | pubmed-6566831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65668312019-06-17 The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice Nakaoku, Yuriko Saito, Satoshi Yamamoto, Yumi Maki, Takakuni Takahashi, Ryosuke Ihara, Masafumi Int J Mol Sci Article Vascular risk factors, such as type 2 diabetes mellitus (T2DM), are associated with the increased risk of Alzheimer’s disease. One of the common T2DM medications, dipeptidyl peptidase (DPP)-4 inhibitors, have a minimum risk for hypoglycemia and have recently been suggested to ameliorate β-amyloid pathology. However, conflicting results have been reported regarding the effects of DPP-4 inhibition on cognitive function and tau pathology. Thus, we investigated whether inhibiting DPP-4 affects tau pathology and cognition in a mouse model of tauopathy with hyperglycemia. Male mice overexpressing the P301S mutant human microtubule-associated protein tau gene (PS19) were fed either a low or high-fat diet. PS19 mice were then administered either linagliptin, a DPP-4 inhibitor, or vehicle, from 6 weeks to 8 months of age. Linagliptin-treated mice exhibited higher levels of glucagon-like peptide-1 and decreased fasting blood glucose, compared with the vehicle-treated mice at 8 months. Linagliptin treatment significantly restored spatial reference memory and increased cerebral blood flow without affecting phosphorylation levels of tau or endothelial nitric oxide synthase (eNOS) in the brain. Linagliptin may ameliorate HFD-induced cognitive worsening in tauopathy, at least partially, by increasing cerebral perfusion via the eNOS-independent pathway. MDPI 2019-05-23 /pmc/articles/PMC6566831/ /pubmed/31126115 http://dx.doi.org/10.3390/ijms20102539 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nakaoku, Yuriko Saito, Satoshi Yamamoto, Yumi Maki, Takakuni Takahashi, Ryosuke Ihara, Masafumi The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice |
title | The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice |
title_full | The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice |
title_fullStr | The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice |
title_full_unstemmed | The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice |
title_short | The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice |
title_sort | dipeptidyl peptidase-4 inhibitor linagliptin ameliorates high-fat induced cognitive decline in tauopathy model mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566831/ https://www.ncbi.nlm.nih.gov/pubmed/31126115 http://dx.doi.org/10.3390/ijms20102539 |
work_keys_str_mv | AT nakaokuyuriko thedipeptidylpeptidase4inhibitorlinagliptinameliorateshighfatinducedcognitivedeclineintauopathymodelmice AT saitosatoshi thedipeptidylpeptidase4inhibitorlinagliptinameliorateshighfatinducedcognitivedeclineintauopathymodelmice AT yamamotoyumi thedipeptidylpeptidase4inhibitorlinagliptinameliorateshighfatinducedcognitivedeclineintauopathymodelmice AT makitakakuni thedipeptidylpeptidase4inhibitorlinagliptinameliorateshighfatinducedcognitivedeclineintauopathymodelmice AT takahashiryosuke thedipeptidylpeptidase4inhibitorlinagliptinameliorateshighfatinducedcognitivedeclineintauopathymodelmice AT iharamasafumi thedipeptidylpeptidase4inhibitorlinagliptinameliorateshighfatinducedcognitivedeclineintauopathymodelmice AT nakaokuyuriko dipeptidylpeptidase4inhibitorlinagliptinameliorateshighfatinducedcognitivedeclineintauopathymodelmice AT saitosatoshi dipeptidylpeptidase4inhibitorlinagliptinameliorateshighfatinducedcognitivedeclineintauopathymodelmice AT yamamotoyumi dipeptidylpeptidase4inhibitorlinagliptinameliorateshighfatinducedcognitivedeclineintauopathymodelmice AT makitakakuni dipeptidylpeptidase4inhibitorlinagliptinameliorateshighfatinducedcognitivedeclineintauopathymodelmice AT takahashiryosuke dipeptidylpeptidase4inhibitorlinagliptinameliorateshighfatinducedcognitivedeclineintauopathymodelmice AT iharamasafumi dipeptidylpeptidase4inhibitorlinagliptinameliorateshighfatinducedcognitivedeclineintauopathymodelmice |